News

2024/09/16

Antennova Releases Latest Data of CD73 Inhibitor ATN-037, Including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

more
2024/09/05

Antennova Announces Parent Company Antengene’s Participation in the H.C. Wainwright 26th Annual Global Investment Conference

more
2024/08/05

Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024

more
2024/03/20

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

more